Randy1111
2 years ago
Great just GREAT!!!!!!
This is turning into a piece of crap. Who lets a Nasdaq company fall . Just sucks.
September 29, 2022 - 8:30 am
TORONTOFSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced that on September 27, 2022 it received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq's rules for continued listing on the Nasdaq Capital Market. The Notification Letter is only a notification of deficiency and not a notice of delisting. As such, the Notification Letter has no effect on the listing or trading of the Company's Class B Subordinate Voting Shares on the Nasdaq.
Nasdaq Listing Rule 5550(a)(2) requires securities listed on the Nasdaq Capital Market to maintain a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's Class B Subordinate Voting Shares for the 30 consecutive business days from August 15, 2022 to September 26, 2022, the Company has not met the minimum bid price requirement.
Randy1111
3 years ago
The clown show is over. FSD has turned in the right direction.
FSD Pharma boots out CEO Raza Bokhari
Jul. 27, 2021 8:57 AM ETFSD Pharma Inc. (HUGE)FSD Pharma Inc. (HUGE)By: Aakash Babu, SA News Editor
FSD Pharma (NASDAQ:HUGE) announces the termination of employment of its chief executive officer Raza Bokhari for cause, following an investigation by an international law firm.
Following the completion of its investigation, the Special Committee made a recommendation to the board of directors and the board unanimously determined to terminate Bokhariโs employment, the company said.
Few of the reasons for Bokhariโs termination are misconduct including breaching court orders, the improper issuance of shares, and attempts to misappropriate company funds in breach of his employment obligations.
The company also said that it had appointed Anthony Durkacz as interim chief executive officer and reinstated Zeeshan Saeed as its president.
FSD Pharma had filed a criminal complaint with the Financial Crimes Unit of Toronto Police against its former CFO Donal Carroll in relation to his alleged interference in the companyโs banking relationships, in May.